Chantez Sanford Jr., 24, of Southfield, says his life has been transformed after undergoing Lyfgenia gene therapy at Children ...
UAB is participating in a Phase I/II trial of AMT 191, a one time gene therapy designed to enable patients with classic Fabry disease to produce their own missing enzyme, potentially reducing the need ...
In an interview ahead of Advanced Therapies Week, Anna Catalanotto of Cardinal Health discussed growth in cell and gene therapies, highlighting that cross-sector collaboration is key to improving ...
Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.
A new chapter is unfolding for gene therapies in Europe. With retinal programs advancing into Phase I/II trials and ...
The Advanced Research Projects Agency for Health ( ARPA-H) awarded BioCurie up to $9.3 million to accelerate the development of scalable, data-driven genomic medicine production.
UniQure’s AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain. ・The FDA recently said that data ...
Researchers have found a promising new method for gene therapy. They successfully restarted inactive genes by bringing them closer to genetic switches on the DNA called enhancers. The intermediate ...
Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.
The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary -- The ...
Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by ...